IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: § Confirmation Number: 1791 Stephen Maxwell Taylor Ian Alexander Shiels § Lindsay Charles Brown Michael Whitehouse (As Amended) Group Art Unit: Unknown Application Number: 10/510,614 PCT Number: PCT/AU03/00415 International Filing Date: 7 April 2003 Examiner: Unknown § Attorney Docket No: 36677.30 **USE OF C5A RECEPTOR** For: (formerly 4050.003000) ANTAGONIST IN THE TREATMENT OF FIBROSIS

STATEMENT OF JOINT INVENTOR MICHAEL WHITEHOUSE UNDER 37 C. F. R. § 1.497(d)(1)

Mail Stop PCT Commissioner for Patents Office of Legal Administration P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Certificate of Mailing 37 C. F. R. § 1.8

I hereby certify that this correspondence is being deposited with the U. S. Postal Service with sufficient postage as First Class Mail on the date indicated below and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

Author Y.L. BROWN

Name of person mailing paper and fee

Signature of person mailing paper and fee

I, MICHAEL WHITEHOUSE, HEREBY DECLARE AS FOLLOWS:

1. The PCT application to which the above-referenced U.S. national stage application claims priority was originally filed listing Stephen Maxwell Taylor, Ian Alexander Shiels, and Lindsay Charles Brown, as joint inventors.

MW

Application Number: 10/510,614 Customer Number: 000027683

- 2. It was determined that I, Michael Whitehouse, am also a proper joint inventor for the above-referenced U.S. national stage application.
- 3. I was added as a joint inventor after entry in the US national stage application by Applicants' filing a Declaration on 11 October 2005 (A copy of which is attached hereto).
- 4. My omission as a co-inventor of the PCT application was an inadvertent oversight, which occurred without deceptive intent on my part.
- 5. My omission as a co-inventor on the above-referenced U.S. national stage application, was also an inadvertent oversight, which also occurred without deceptive intent on my part.
- 6. I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U. S. C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

H April 2006

Date

Michael Whitehouse

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Stephen Maxwell Taylor
Ian Alexander Shiels
Lindsay Charles Brown
Michael Whitehouse (As Amended)

Application Number: 10/510,614
PCT Number: PCT/AU03/00415

International Filing Date: 7 April 2003

For: USE OF C5A RECEPTOR ANTAGONIST § Confirmation Number: 1791

CONSENT OF ASSIGNEE TO ADD INVENTOR

Certificate of Mailing 37 C. F. R. § 1.8 I hereby certify that this correspondence is being deposited with the U. S. Postal Service with sufficient postage as First Class Mail

Mail Stop PCT
Commissioner for Patents
Office of PCT Legal Administration
P.O. Box 1450
Alexandria, VA 22313-1450

IN THE TREATMENT OF FIBROSIS

Dear Sir:

The undersigned, Promics Pty Limited, being the assignee of record of the entire interest in the above-identified application by virtue of Assignments concurrently submitted for recordation in the U.S. Patent and Trademark Office, hereby consents to the addition of Michael Whitehouse as a joint inventor in the above-captioned patent application.

ASSIGNEE: PROMICA PTY LIMITED

By: Lan Scott

Name: Alan Scott

Title: Managing Director

Date: April 1th 2006

1450.

Application Number: 10/510,614 PCT Number: PCT/AU03/00415

The PCT application to which the above-referenced U.S. application claims priority PCT/AU03/00415, was filed listing Stephen Maxwell Taylor, Ian Alexander Shiels, and Lindsay Charles Brown as joint inventors. Michael Whitehouse was inadvertently omitted as a joint inventor to the PCT Application. Subsequently on entry into the U.S. national stage, the inventors for the U.S. application were identified as Stephen Maxwell Taylor, Ian Alexander Shiels, and Lindsay Charles Brown. After filing, it was also determined that Michael Whitehouse was a proper joint inventor of the U.S. application and was so identified on the Declaration.

Therefore, Applicants request the addition of Michael Whitehouse for the present application.

The required processing fee of \$130.00 is authorized to be charged to Deposit Account No. 08-1394. The Commissioner is hereby authorized to charge any further fees associated with this communication, or to credit any overpayment, to Deposit Account of Haynes and Boone, LLP Number 08-1394.

Respectfully submitted,

/www.

Mark D. Moore, Ph.D. Registration No. 42,903

Date: OS/05/06 HAYNES AND BOONE, LLP 901 Main Street, Suite 3100 Dallas, Texas 75202-3789

Telephone: 713-547-2040 Facsimile: 214-200-0853

H-605736.1



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCTOBER 19, 2005

PTAS

500055931A

500055931A

MARK D. MOORE 901 MAIN STREET SUITE 3100 DALLAS, TX 75202

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES DIVISION, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 10/19/2005

REEL/FRAME: 016658/0335

NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 36677.30

ASSIGNOR:

MAXWELL, STEPHEN TAYLOR

DOC DATE: 08/05/2005

ASSIGNOR:

SHIELS, IAN ALEXANDER

DOC. DATE: 08/05/2005

ASSIGNOR:

BROWN, LINDSAY CHARLES

DOC DATE: 08/05/2005

016658/0335 PAGE 2

ASSIGNEE:

PROMICS PTY. LIMITED
BUILDING 64, PHYSIOLOGY &
PHARMACOLOGY DEPT.
UNIVERSITY OF QUEENSLAND, ST.
LUCIA
QUEENSLAND, AUSTRALIA 4072

SERIAL NUMBER: 10510614

PATENT NUMBER:

TITLE: THERAPEUTIC METHOD

FILING DATE: ISSUE DATE:

JEFFREY OLSEN, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1 10/19/2005 500055931

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Stephen Taylor Maxwell	08/05/2005
lan Alexander Shleis	08/05/2005
Lindsay Charles Brown	08/05/2005

RECEIVING PARTY DATA

Name:	Promics Pty. Limited	
Street Address:	Building 64, Physiology & Pharmacology Dept.	
Internal Address:	University of Queensland, St. Lucia	
City:	Queensland	
State/Country:	AUSTRALIA	
Postal Code:	4072	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	10510614

CORRESPONDENCE DATA

Fax Number:

(214)200-0853

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone:

713-547-2040

Email:

ipdocketing@haynesboone.com

Correspondent Name: Address Line 1:

Mark D. Moore

Address Line 2:

901 Main Street

ADDIESS LINE 2:

Sulte 3100

Address Line 4:

Dallas, TEXAS 75202

ATTORNEY DOCKET NUMBER:	36877.30
NAME OF SUBMITTER:	Mark D. Moore

Total Attachments: 2 source=30 executed assignment#page1.tif source=30 executed assignment#page2.tif

ASSIGNMENT

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, the undersigned, do hereby:

SELL, ASSIGN AND TRANSFER to Promics Pty Limited (the "Assignee"), having a place of business at Building 64, Physiology & Pharmacology Dept., University of Queensland, St. Lucia, Queensland 4072, Australia, the entire right, title and interest for the United States and all foreign countries in and to any and all improvements which are disclosed in the application for United States Letters Patent, Serial No. 10/510,614 which has been filed on October 07, 2004 and is entitled "Use of C5A Receptor Antagonist in the Treatment of Fibrosis", such application and all divisional, continuing, substitute, renewal, reissue and all other applications for patent which have been or shall be filed in the United States and all foreign countries on any of such improvements; all original and reissued patents which have been or shall be issued in the United States and all foreign countries on such improvements; and specifically including the right to file foreign applications under the provisions of any convention or treaty and claim priority based on such application in the United States;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such improvements to the Assignee;

WARRANT AND COVENANT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned;

COVENANT, when requested and at the expense of the Assignee, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all such improvements; execute all rightful oaths, declarations, assignments, powers of attorney and other papers; communicate to the Assignce all facts known to the undersigned relating to such improvements and the history thereof; and generally do everything possible which the Assignee shall consider desirable for vesting title to such improvements in the Assignee, and for securing, maintaining and enforcing proper patent protection for such improvements;

TO BE BINDING on the heirs, assigns, representatives and successors of the undersigned and extend to the successors, assigns and nominees of the Assignee.

Signature:

Date

August 2005

Witness' Signature: